Reported 2 days ago
Teva Pharmaceutical Industries has received FDA approval to expand the use of UZEDY (risperidone) for the maintenance treatment of Bipolar I Disorder (BD-I) in adults, allowing it to be used alone or with lithium or valproate. This long-acting formulation offers three dosing options and aims to meet the needs of the approximately 3.4 million adults in the U.S. affected by this mental health condition. The FDA's decision is based on existing clinical data supporting the drug's efficacy.
Source: YAHOO